Historically, drug research and development data, as well as the production and distribution of product information, has been the exclusive domain of the pharmaceutical companies.
Nowadays, new competitors, such as technology companies, are entering the playing field, providing a new form of engagement with customers and stakeholders. The pharmaceutical companies’ stranglehold over business and information on industrial processes is now in tatters.
Stricter regulatory and safety guidelines, as well as pressure to become more cost-effective, responsive and streamlined, are compelling the pharmaceutical companies to act swiftly and decisively to deploy cutting-edge technologies to simplify their business and improve production processes. In this environment, digitalisation is the way forward in promoting paperless manufacturing within regulated processes.
Sónia Veiga Macedo